In 2026, Fresenius Medical (FMS) Care expects revenue growth to be broadly flat compared to prior year. The company expects operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year. The expected growth rates for 2026 are at constant currency and excluding special items in operating income. The 2025 basis for the revenue outlook is EUR19.628B and for the operating income outlook is EUR2.212B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care: Weaker Growth, Limited Margin Visibility Keep Underperform Rating as €32 Price Target Reaffirmed
- Fresenius Medical Care Posts Strong Q1 2026 Operating Gains Amid Costly U.S. Clinic Restructuring
- FMS Earnings this Week: How Will it Perform?
- Fresenius Medical price target raised to EUR 40 from EUR 39.50 at Citi
- Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact